Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antineoplastic Agents, Alkylating"" wg kryterium: Temat


Tytuł :
Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer.
Autorzy :
Krishnamurthy S; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.; Division of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.; Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Yoda H; Division of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.
Hiraoka K; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Inoue T; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Lin J; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Shinozaki Y; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Watanabe T; Division of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.
Koshikawa N; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Takatori A; Division of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.
Nagase H; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 Mar; Vol. 112 (3), pp. 1141-1149. Date of Electronic Publication: 2021 Jan 21.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Alkylating/*pharmacology
Class I Phosphatidylinositol 3-Kinases/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Uterine Cervical Neoplasms/*drug therapy
Animals ; Antineoplastic Agents, Alkylating/chemical synthesis ; Antineoplastic Agents, Alkylating/therapeutic use ; Cell Line, Tumor ; Cell Survival/drug effects ; Class I Phosphatidylinositol 3-Kinases/genetics ; Female ; Gain of Function Mutation ; Humans ; Imidazoles/chemical synthesis ; Imidazoles/pharmacology ; Imidazoles/therapeutic use ; Mice ; Nylons/chemical synthesis ; Nylons/pharmacology ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/therapeutic use ; Pyrroles/chemical synthesis ; Pyrroles/pharmacology ; Pyrroles/therapeutic use ; Uterine Cervical Neoplasms/genetics ; Uterine Cervical Neoplasms/pathology ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Incidence of hemorrhagic cystitis after cyclophosphamide therapy with or without mesna: A cohort study and comprehensive literature review.
Autorzy :
Almalag HM; Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Alasmari SS; Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Alrayes MH; Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Binhameed MA; Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Alsudairi RA; Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Alosaimi MM; Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Alnasser GA; Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Abuzaid RA; Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Khalil N; Department of Medicine, Rheumatology Unite, King Saud University and Medical City, Riyadh, Saudi Arabia.
Abouzaid HH; Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Alarfaj AS; Department of Medicine, Rheumatology Unite, King Saud University and Medical City, Riyadh, Saudi Arabia.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2021 Mar; Vol. 27 (2), pp. 340-349. Date of Electronic Publication: 2020 May 01.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Antineoplastic Agents, Alkylating/*adverse effects
Cyclophosphamide/*adverse effects
Cystitis/*chemically induced
Hemorrhage/*chemically induced
Mesna/*therapeutic use
Protective Agents/*therapeutic use
Adult ; Antineoplastic Agents, Alkylating/administration & dosage ; Cohort Studies ; Cyclophosphamide/administration & dosage ; Cystitis/prevention & control ; Female ; Hemorrhage/prevention & control ; Humans ; Male ; Middle Aged ; Prospective Studies ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Long-Term Near-Infrared Signal Tracking of the Therapeutic Changes of Glioblastoma Cells in Brain Tissue with Ultrasound-Guided Persistent Luminescent Nanocomposites.
Autorzy :
Cheng CL; Department of Chemistry, National Taiwan University, Taipei 10617, Taiwan.
Chan MH; Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan.
Feng SJ; Department of Chemistry, National Taiwan University, Taipei 10617, Taiwan.
Hsiao M; Genomics Research Center, Academia Sinica, Taipei 11529, Taiwan.; Department of Biochemistry, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
Liu RS; Department of Chemistry, National Taiwan University, Taipei 10617, Taiwan.
Pokaż więcej
Źródło :
ACS applied materials & interfaces [ACS Appl Mater Interfaces] 2021 Feb 10; Vol. 13 (5), pp. 6099-6108. Date of Electronic Publication: 2021 Jan 28.
Typ publikacji :
Journal Article
MeSH Terms :
Ultrasonic Therapy*
Antineoplastic Agents, Alkylating/*pharmacology
Brain Neoplasms/*therapy
Glioblastoma/*therapy
Nanocomposites/*chemistry
Temozolomide/*pharmacology
Animals ; Antineoplastic Agents, Alkylating/chemistry ; Blood-Brain Barrier/drug effects ; Brain Neoplasms/pathology ; Cell Line, Tumor ; Cell Survival/drug effects ; Glioblastoma/pathology ; Humans ; Infrared Rays ; Molecular Structure ; Neoplasms, Experimental/pathology ; Neoplasms, Experimental/therapy ; Particle Size ; Surface Properties ; Temozolomide/chemistry ; Ultrasonic Waves
Czasopismo naukowe
Tytuł :
Glioma and temozolomide induced alterations in gut microbiome.
Autorzy :
Patrizz A; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Dono A; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.; Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Zorofchian S; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.; Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Hines G; Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Takayasu T; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.; Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Husein N; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Otani Y; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Arevalo O; Department of Diagnostic and Interventional Imaging, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Choi HA; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Savarraj J; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Tandon N; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Ganesh BP; Department of Neurology, The University of Texas Health Science Center At Houston, McGovern Medical School, Houston, TX, USA.
Kaur B; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
McCullough LD; Department of Neurology, The University of Texas Health Science Center At Houston, McGovern Medical School, Houston, TX, USA.
Ballester LY; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA. .; Department of Pathology and Laboratory Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA. .; Memorial Hermann Hospital-TMC, Houston, TX, USA. .; Department of Pathology & Laboratory Medicine and Department of Neurosurgery, The University of Texas Health Science Center at Houston - McGovern Medical School, 6431 Fannin Street, MSB 2.136, Houston, TX, 77030, USA. .
Esquenazi Y; Vivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA. .; Center for Precision Health, The University of Texas Health Science Center At Houston, McGovern Medical School, Houston, TX, USA. .; Memorial Hermann Hospital-TMC, Houston, TX, USA. .; Vivian L. Smith Department of Neurosurgery and Center for Precision Health, The University of Texas Health Science Center at Houston - McGovern Medical School, 6400 Fannin Street, Suite # 2800, Houston, TX, 77030, USA. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Dec 03; Vol. 10 (1), pp. 21002. Date of Electronic Publication: 2020 Dec 03.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Gastrointestinal Microbiome*
Antineoplastic Agents, Alkylating/*adverse effects
Brain Neoplasms/*microbiology
Dysbiosis/*etiology
Glioma/*microbiology
Temozolomide/*adverse effects
Adolescent ; Adult ; Animals ; Antineoplastic Agents, Alkylating/therapeutic use ; Brain Neoplasms/drug therapy ; Female ; Glioma/drug therapy ; Humans ; Male ; Mice ; Mice, Inbred C57BL ; Middle Aged ; Temozolomide/therapeutic use
Czasopismo naukowe
Tytuł :
Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma.
Autorzy :
de Sande González LM; Medical Oncology Department, Leon University Hospital , León, Spain.
Martin-Broto J; MUsculoSkeletal Tumor Board of Excellence Sevilla (MUSTBE SEVILLA), Virgen del Rocío University Hospital , Sevilla, Spain.
Kasper B; Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, University Medical Center, University of Heidelberg, Theodor‑Kutzer‑Ufer , Mannheim, Germany.
Blay JY; Medical Oncology Department, Centre Léon Bérard , Lyon, France.; Medical Oncology Department, Université Claude Bernard Lyon I , Lyon, France.
Le Cesne A; Medical Oncology Department, Gustave Roussy , Villejuif, France.
Pokaż więcej
Źródło :
Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2020 Nov; Vol. 20 (11), pp. 957-963. Date of Electronic Publication: 2020 Sep 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antineoplastic Agents, Alkylating/*administration & dosage
Sarcoma/*drug therapy
Trabectedin/*administration & dosage
Antineoplastic Agents, Alkylating/adverse effects ; Humans ; Leiomyosarcoma/drug therapy ; Leiomyosarcoma/pathology ; Liposarcoma/drug therapy ; Liposarcoma/pathology ; Quality of Life ; Randomized Controlled Trials as Topic ; Sarcoma/pathology ; Trabectedin/adverse effects
Czasopismo naukowe
Tytuł :
Melflufen for relapsed and refractory multiple myeloma.
Autorzy :
Oriol A; Institut Josep Carreras and Institut Català d'Oncologia, Hospital Germans Trias I Pujol , Badalona, Spain.
Larocca A; Azienda Ospedaliero-Universitaria Città Della Salute E Della Scienza Di Torino, University of Torino , Torino, Italy.
Leleu X; Department of Hematology, Hôpital De La Milétrie, CHU De Poitiers , Poitiers, France.
Hajek R; Department of Hemato-Oncology, University of Ostrava and Faculty of Medicine, University of Ostrava , Ostrava, Czech Republic.
Hassoun H; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA.
Rodríguez-Otero P; Department of Hematology, Clínica Universidad De Navarra , Pamplona, Spain.
Paner A; Division of Hematology, Oncology and Stem Cell Transplant, Rush University Medical Center , Chicago, IL, USA.
Schjesvold FH; Oslo Myeloma Center, Oslo University Hospital and K.G. Jebsen Centre for B-Cell Malignancies, University of Oslo , Oslo, Norway.
Gullbo J; Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University , Uppsala, Sweden.
Richardson PG; Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA, USA.
Pokaż więcej
Źródło :
Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2020 Oct; Vol. 29 (10), pp. 1069-1078. Date of Electronic Publication: 2020 Sep 29.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Agents, Alkylating/*administration & dosage
Melphalan/*analogs & derivatives
Multiple Myeloma/*drug therapy
Phenylalanine/*analogs & derivatives
Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Alkylating/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Humans ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Melphalan/pharmacology ; Multiple Myeloma/pathology ; Phenylalanine/administration & dosage ; Phenylalanine/adverse effects ; Phenylalanine/pharmacology ; Recurrence ; Survival Rate
Czasopismo naukowe
Tytuł :
A two-photon responsive naphthyl tagged p-hydroxyphenacyl based drug delivery system: uncaging of anti-cancer drug in the phototherapeutic window with real-time monitoring.
Autorzy :
Singh AK; Department of Chemistry, Indian Institute of Technology Kharagpur, 721302 Kharagpur, West Bengal, India. .
Kundu M
Roy S
Roy B
Shah SS
Nair AV
Pal B
Mondal M
Singh NDP
Pokaż więcej
Źródło :
Chemical communications (Cambridge, England) [Chem Commun (Camb)] 2020 Sep 07; Vol. 56 (69), pp. 9986-9989. Date of Electronic Publication: 2020 Jul 28.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Alkylating/*chemistry
Chlorambucil/*chemistry
Drug Carriers/*chemistry
Naphthalenes/*chemistry
Antineoplastic Agents, Alkylating/metabolism ; Antineoplastic Agents, Alkylating/pharmacology ; Cell Survival/drug effects ; Chlorambucil/metabolism ; Chlorambucil/pharmacology ; Drug Liberation ; Humans ; Light ; MCF-7 Cells ; Microscopy, Confocal ; Photons
Czasopismo naukowe
Tytuł :
Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy.
Autorzy :
Chiesa S; UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, largo A. Gemelli 1, 00168, Rome, Italy.
Hohaus S; UOC di Ematologia, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Falcinelli L; Sezione di Radioterapia Oncologica, Dipartimento di Chirurgia e Scienze Biomedicali, Università degli studi di Perugia, Azienda Ospedaliera di Perugia, Perugia, Italy.
D'Alò F; UOC di Ematologia, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Martelli MF; Divisione di Ematologia, Immunologia Clinica e Trapianto di midollo osseo, Dipartimento di Medicina, Università degli studi di Perugia, Azienda Ospedaliera di Perugia, Perugia, Italy.
Manfrida S; UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, largo A. Gemelli 1, 00168, Rome, Italy.
Beghella Bartoli F; UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, largo A. Gemelli 1, 00168, Rome, Italy. .
Colosimo C; Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy.; UOC di Neuroradiologia, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Valentini V; UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, largo A. Gemelli 1, 00168, Rome, Italy.; Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Aristei C; Sezione di Radioterapia Oncologica, Dipartimento di Chirurgia e Scienze Biomedicali, Università degli studi di Perugia, Azienda Ospedaliera di Perugia, Perugia, Italy.; Struttura Complessa di Radioterapia Oncologica, Azienda Ospedaliera di Perugia, Perugia, Italy.
Balducci M; UOC di Radioterapia Oncologica, Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, largo A. Gemelli 1, 00168, Rome, Italy.; Istituto di Radiologia, Università Cattolica del Sacro Cuore, Rome, Italy.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Oct; Vol. 99 (10), pp. 2367-2375. Date of Electronic Publication: 2020 Aug 20.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study
MeSH Terms :
Chemoradiotherapy*
Cranial Irradiation*
Antineoplastic Agents, Alkylating/*therapeutic use
Brain Neoplasms/*therapy
Lymphoma, Non-Hodgkin/*therapy
Temozolomide/*therapeutic use
Adolescent ; Adult ; Aged ; Antimetabolites, Antineoplastic/therapeutic use ; Antineoplastic Agents, Alkylating/adverse effects ; Brain Neoplasms/drug therapy ; Brain Neoplasms/pathology ; Chemical and Drug Induced Liver Injury/etiology ; Chemotherapy, Adjuvant ; Cognition Disorders/chemically induced ; Consolidation Chemotherapy ; Female ; Hematologic Diseases/chemically induced ; Humans ; Kaplan-Meier Estimate ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, Non-Hodgkin/pathology ; Male ; Maximum Tolerated Dose ; Methotrexate/administration & dosage ; Methotrexate/therapeutic use ; Middle Aged ; Neoplasm, Residual ; Progression-Free Survival ; Prospective Studies ; Temozolomide/adverse effects ; Young Adult
Czasopismo naukowe
Tytuł :
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma.
Autorzy :
Liu Y; Department of Neurosurgery, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A. .
Strawderman MS; Department of Biostatistics and Computational Biology, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.; Wilmot Cancer Institute, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.
Warren KT; School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.
Richardson M; Wilmot Cancer Institute, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.
Serventi JN; Wilmot Cancer Institute, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.; Department of Neurology, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.
Mohile NA; Wilmot Cancer Institute, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.; Department of Neurology, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.
Milano MT; Wilmot Cancer Institute, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.; Department of Radiation Oncology, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.
Walter KA; Department of Neurosurgery, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A. .; Wilmot Cancer Institute, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.; Department of Orthopedics, School of Medicine and Dentistry, University of Rochester, Rochester, NY, U.S.A.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2020 Oct; Vol. 40 (10), pp. 5801-5806.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Alkylating/*administration & dosage
Brain Neoplasms/*drug therapy
Glioblastoma/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Alkylating/adverse effects ; Brain Neoplasms/epidemiology ; Brain Neoplasms/pathology ; Combined Modality Therapy ; Dacarbazine/administration & dosage ; Dacarbazine/adverse effects ; Disease-Free Survival ; Female ; Glioblastoma/epidemiology ; Glioblastoma/pathology ; Humans ; Male ; Middle Aged ; Survival Rate ; Temozolomide/administration & dosage ; Temozolomide/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Cystoid macular edema following intravitreal chemotherapy treatment for retinoblastoma.
Autorzy :
Panthagani J; Birmingham Children's Hospital, Birmingham, UK.
Montecinos P; Calvo Mackena Children´s Hospital Ophthalmology Department, University of Chile, Santiago, Chile.
López JP; Calvo Mackena Children´s Hospital Ophthalmology Department, University of Chile, Santiago, Chile.
Parulekar M; Birmingham Children's Hospital, Birmingham, UK.
Pokaż więcej
Źródło :
Pediatric blood & cancer [Pediatr Blood Cancer] 2020 Sep; Vol. 67 (9), pp. e28348. Date of Electronic Publication: 2020 Jul 07.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Antineoplastic Agents, Alkylating/*adverse effects
Macular Edema/*chemically induced
Melphalan/*adverse effects
Retinal Neoplasms/*drug therapy
Retinoblastoma/*drug therapy
Antineoplastic Agents, Alkylating/therapeutic use ; Child, Preschool ; Female ; Humans ; Infant ; Intravitreal Injections ; Macular Edema/pathology ; Male ; Melphalan/therapeutic use ; Retina/pathology ; Tomography, Optical Coherence ; Visual Acuity/drug effects
Raport
Tytuł :
Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study.
Autorzy :
Kim EJ; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia. Electronic address: .
Geskin L; Department of Dermatology, Columbia University, New York, New York.
Guitart J; Department of Dermatology, Northwestern University, Chicago, Illinois.
Querfeld C; Division of Dermatology, City of Hope, Duarte, California.
Girardi M; Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Musiek A; Division of Dermatology, Washington University in St. Louis School of Medicine, Saint Louis, Missouri.
Mink DR; Helsinn Therapeutics (US), Inc, Iselin, NJ.
Williams MJ; Helsinn Therapeutics (US), Inc, Iselin, NJ.
Angello JT; ICON Commercialization & Outcomes, Dublin, Ireland.
Bailey WL; ICON Commercialization & Outcomes, Dublin, Ireland.
Pokaż więcej
Źródło :
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2020 Sep; Vol. 83 (3), pp. 928-930. Date of Electronic Publication: 2020 Feb 20.
Typ publikacji :
Letter; Observational Study
MeSH Terms :
Antineoplastic Agents, Alkylating/*administration & dosage
Drug Eruptions/*epidemiology
Mechlorethamine/*administration & dosage
Mycosis Fungoides/*drug therapy
Skin Neoplasms/*drug therapy
Administration, Cutaneous ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Alkylating/adverse effects ; Drug Eruptions/diagnosis ; Drug Eruptions/etiology ; Female ; Gels ; Humans ; Male ; Mechlorethamine/adverse effects ; Middle Aged ; Mycosis Fungoides/complications ; Mycosis Fungoides/diagnosis ; Prospective Studies ; Quality of Life ; Severity of Illness Index ; Skin Neoplasms/complications ; Skin Neoplasms/diagnosis ; Treatment Outcome ; Young Adult
Raport
Tytuł :
Fabrication of chlorambucil loaded graphene- oxide nanocarrier and its application for improved antitumor activity.
Autorzy :
Singh G; Department of Applied Sciences and Humanities, Indira Gandhi Delhi Technical University for Women, Delhi, 110006, India.
Nenavathu BP; Department of Applied Sciences and Humanities, Indira Gandhi Delhi Technical University for Women, Delhi, 110006, India. Electronic address: .
Imtiyaz K; Department of Biosciences, Jamia Millia Islamia University, New Delhi, India.
Moshahid A Rizvi M; Department of Biosciences, Jamia Millia Islamia University, New Delhi, India.
Pokaż więcej
Źródło :
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2020 Sep; Vol. 129, pp. 110443. Date of Electronic Publication: 2020 Jun 24.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Drug Carriers*
Nanoparticles*
Adenocarcinoma/*drug therapy
Antineoplastic Agents, Alkylating/*pharmacology
Chlorambucil/*pharmacology
Graphite/*chemistry
Uterine Cervical Neoplasms/*drug therapy
Adenocarcinoma/pathology ; Antineoplastic Agents, Alkylating/chemistry ; Cell Line, Tumor ; Cell Survival/drug effects ; Chlorambucil/chemistry ; Delayed-Action Preparations ; Dose-Response Relationship, Drug ; Drug Compounding ; Drug Liberation ; Female ; Folic Acid/chemistry ; Gelatin/chemistry ; Humans ; Hydrogen-Ion Concentration ; Inhibitory Concentration 50 ; Kinetics ; Uterine Cervical Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastoma.
Autorzy :
Hsieh T; Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America.; Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
Liao A; Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.; Emory Eye Center, Emory University School of Medicine, Atlanta, GA, United States of America.
Francis JH; Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.; Department of Ophthalmology, Weill-Cornell Medical Center, New York, NY, United States of America.
Lavery JA; Department of Epidemiology & Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
Mauguen A; Department of Epidemiology & Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
Brodie SE; Department of Ophthalmology, NYU Langone Health, New York, NY, United States of America.
Abramson DH; Ophthalmic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.; Department of Ophthalmology, Weill-Cornell Medical Center, New York, NY, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Jul 01; Vol. 15 (7), pp. e0235016. Date of Electronic Publication: 2020 Jul 01 (Print Publication: 2020).
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Antineoplastic Agents, Alkylating/*therapeutic use
Melphalan/*therapeutic use
Retinal Neoplasms/*drug therapy
Retinoblastoma/*drug therapy
Adolescent ; Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Alkylating/adverse effects ; Child ; Child, Preschool ; Humans ; Infant ; Intravitreal Injections ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Retina/drug effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Novel method for fast trabectedin quantification using hydrophilic interaction liquid chromatography and tandem mass spectrometry for human pharmacokinetic studies.
Autorzy :
Di Gregorio E; Immunopathology and Cancer Biomarkers Unit, IRCCS CRO Centro di Riferimento Oncologico Aviano, 33081, Aviano (PN), Italy; Department of Molecular Sciences and Nanosystems, University of Venice, 30170, Mestre (VE), Italy.
Miolo G; Medical Oncology and Cancer Prevention Unit, IRCCS CRO Centro di Riferimento Oncologico Aviano, 33081, Aviano (PN), Italy.
Steffan A; Immunopathology and Cancer Biomarkers Unit, IRCCS CRO Centro di Riferimento Oncologico Aviano, 33081, Aviano (PN), Italy.
Corona G; Immunopathology and Cancer Biomarkers Unit, IRCCS CRO Centro di Riferimento Oncologico Aviano, 33081, Aviano (PN), Italy. Electronic address: .
Pokaż więcej
Źródło :
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2020 Jun 05; Vol. 185, pp. 113261. Date of Electronic Publication: 2020 Mar 17.
Typ publikacji :
Journal Article; Observational Study; Validation Study
MeSH Terms :
Antineoplastic Agents, Alkylating/*blood
Drug Monitoring/*methods
High-Throughput Screening Assays/*methods
Sarcoma/*drug therapy
Trabectedin/*blood
Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Alkylating/pharmacokinetics ; Chromatography, High Pressure Liquid/methods ; Humans ; Hydrophobic and Hydrophilic Interactions ; Limit of Detection ; Reproducibility of Results ; Sarcoma/blood ; Tandem Mass Spectrometry/methods ; Time Factors ; Trabectedin/administration & dosage ; Trabectedin/chemistry ; Trabectedin/pharmacokinetics
Czasopismo naukowe
Tytuł :
UPLC-Tandem Mass Spectrometry for Quantification of Busulfan in Human Plasma: Application to Therapeutic Drug Monitoring.
Autorzy :
Matar KM; Department of Pharmacology & Therapeutics, Faculty of Pharmacy, Kuwait University, Kuwait, Kuwait. .
Alshemmari SH; Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait, Kuwait.
Refaat S; Department of Medical Oncology, Kuwait Cancer Control Center, Kuwait, Kuwait.
Anwar A; Department of Pharmacology & Toxicology, Faculty of Medicine, Kuwait University, Kuwait, Kuwait.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2020 Jun 02; Vol. 10 (1), pp. 8913. Date of Electronic Publication: 2020 Jun 02.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Alkylating/*blood
Busulfan/*blood
Chromatography, High Pressure Liquid/*methods
Tandem Mass Spectrometry/*methods
Adolescent ; Adult ; Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Alkylating/therapeutic use ; Busulfan/administration & dosage ; Busulfan/therapeutic use ; Child ; Child, Preschool ; Dose-Response Relationship, Drug ; Drug Monitoring/methods ; Female ; Hematologic Neoplasms/drug therapy ; Humans ; Male ; Middle Aged ; Young Adult
Czasopismo naukowe
Tytuł :
Age-dependent hemato- and nephrotoxicity in patients with head and neck cancer receiving chemoradiotherapy with weekly cisplatin.
Autorzy :
Weykamp F; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Seidensaal K; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Rieken S; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Green K; Hospital Pharmacy, Heidelberg University Hospital, Heidelberg, Germany.
Mende S; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Zaoui K; Department of Otorhinolaryngology, Heidelberg University Hospital, Heidelberg, Germany.
Freier K; Department of Oral and Maxillofacial Surgery, Saarland University Medical Center, Homburg, Germany.
Adeberg S; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.
Debus J; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.; National Center for Tumor diseases (NCT), Heidelberg, Germany.; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), partner site Heidelberg, Heidelberg, Germany.
Welte SE; Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany. .; Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany. .; National Center for Tumor diseases (NCT), Heidelberg, Germany. .
Pokaż więcej
Transliterated Title :
Altersabhängige Hämato- und Nephrotoxizität bei Patienten mit Kopf-Hals-Tumoren unter Radiochemotherapie mit wöchentlicher Cisplatin-Gabe.
Źródło :
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2020 Jun; Vol. 196 (6), pp. 515-521. Date of Electronic Publication: 2019 Nov 29.
Typ publikacji :
Journal Article
MeSH Terms :
Radiotherapy, Intensity-Modulated*
Acute Kidney Injury/*chemically induced
Antineoplastic Agents, Alkylating/*adverse effects
Chemoradiotherapy/*adverse effects
Cisplatin/*adverse effects
Head and Neck Neoplasms/*therapy
Leukopenia/*chemically induced
Squamous Cell Carcinoma of Head and Neck/*therapy
Adolescent ; Adult ; Age Factors ; Aged ; Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Alkylating/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cisplatin/administration & dosage ; Cisplatin/therapeutic use ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Head and Neck Neoplasms/mortality ; Heavy Ion Radiotherapy ; Humans ; Kaplan-Meier Estimate ; Lymphatic Irradiation ; Lymphatic Metastasis/therapy ; Male ; Middle Aged ; Progression-Free Survival ; Retrospective Studies ; Squamous Cell Carcinoma of Head and Neck/mortality ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Autorzy :
Richardson PG; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: .
Bringhen S; Division of Haematology, University of Torino, Azienda Ospedaliero-Universitaria, Città della Salute e della Scienza di Torino, Torino, Italy.
Voorhees P; Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Plesner T; Department of Haematology, Vejle Hospital, Vejle, Denmark.
Mellqvist UH; Department of Haematology, Borås Hospital, Borås, Sweden.
Reeves B; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Paba-Prada C; Miami Cancer Institute at Baptist Health South Florida, Miami, FL, USA.
Zubair H; Oncopeptides AB, Stockholm, Sweden.
Byrne C; Oncopeptides AB, Stockholm, Sweden.
Chauhan D; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Anderson K; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Nordström E; Oncopeptides AB, Stockholm, Sweden.
Harmenberg J; Oncopeptides AB, Stockholm, Sweden.
Palumbo A; GlaxoSmithKline, Zug, Switzerland.
Sonneveld P; Department of Haematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2020 May; Vol. 7 (5), pp. e395-e407. Date of Electronic Publication: 2020 Mar 23.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Agents, Alkylating/*therapeutic use
Antineoplastic Agents, Hormonal/*therapeutic use
Dexamethasone/*therapeutic use
Melphalan/*analogs & derivatives
Multiple Myeloma/*drug therapy
Phenylalanine/*analogs & derivatives
Aged ; Antineoplastic Agents, Alkylating/administration & dosage ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Hormonal/administration & dosage ; Antineoplastic Agents, Hormonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Maximum Tolerated Dose ; Melphalan/administration & dosage ; Melphalan/adverse effects ; Melphalan/therapeutic use ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Phenylalanine/administration & dosage ; Phenylalanine/adverse effects ; Phenylalanine/therapeutic use
Czasopismo naukowe
Tytuł :
Causes and possibilities to circumvent cyclophosphamide toxicity.
Autorzy :
Voelcker G; Institute of Biochemistry II, Goethe University Frankfurt Medical School, Frankfurt, Germany.
Pokaż więcej
Źródło :
Anti-cancer drugs [Anticancer Drugs] 2020 Jul; Vol. 31 (6), pp. 617-622.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents, Alkylating/*toxicity
Cell Proliferation/*drug effects
Cyclophosphamide/*analogs & derivatives
Cyclophosphamide/*toxicity
Leukemia P388/*pathology
Phosphoramide Mustards/*toxicity
Animals ; Antineoplastic Agents, Alkylating/chemistry ; Cyclophosphamide/chemistry ; Female ; Leukemia P388/drug therapy ; Male ; Mice ; Phosphoramide Mustards/chemistry ; Toxicity Tests
Czasopismo naukowe
Tytuł :
Brain metastases from esophageal cancer: A case report.
Autorzy :
Qie S; Department of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, Hebei, China.
Ran Y
Yang H
Cui G
Liu M
Sun X
Tian Y
Sun W
Li N
Liu C
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Jun 12; Vol. 99 (24), pp. e20223.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Antineoplastic Agents, Alkylating/*therapeutic use
Brain Neoplasms/*secondary
Esophageal Neoplasms/*pathology
Temozolomide/*therapeutic use
Administration, Oral ; Aftercare ; Aged ; Antineoplastic Agents, Alkylating/administration & dosage ; Brain Neoplasms/diagnostic imaging ; Brain Neoplasms/therapy ; Combined Modality Therapy/methods ; Esophageal Neoplasms/radiotherapy ; Female ; Humans ; Magnetic Resonance Imaging/methods ; Neoplasm Metastasis/pathology ; Radiotherapy/methods ; Temozolomide/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Cyclophosphamide desensitization in patients with severe hypersensitivity reactions to bendamustine.
Autorzy :
Figgins B; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, USA.; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, USA.
Primeaux B; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, USA.
Shank BR; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, USA.
Chen SE; Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, USA.
Weber DM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
Lu H; Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2020 Jun; Vol. 26 (4), pp. 982-985. Date of Electronic Publication: 2019 Aug 21.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Severity of Illness Index*
Antineoplastic Agents, Alkylating/*therapeutic use
Bendamustine Hydrochloride/*adverse effects
Cyclophosphamide/*therapeutic use
Desensitization, Immunologic/*methods
Drug Hypersensitivity/*diagnosis
Aged ; Antineoplastic Agents, Alkylating/adverse effects ; Drug Hypersensitivity/drug therapy ; Female ; Humans ; Middle Aged
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies